Frontotemporal degeneration, the next therapeutic frontier: Molecules and animal models for frontotemporal degeneration drug development

@article{Boxer2013FrontotemporalDT,
  title={Frontotemporal degeneration, the next therapeutic frontier: Molecules and animal models for frontotemporal degeneration drug development},
  author={Adam L. Boxer and Michael Mar. Gold and Edward D. Huey and Fen-Biao Gao and Jeffrey L. Cummings},
  journal={Alzheimer's & Dementia},
  year={2013},
  volume={9},
  pages={176-188}
}
Frontotemporal degeneration (FTD) is a common cause of dementia for which there are currently no approved therapies. Over the past decade, there has been an explosion of knowledge about the biology and clinical features of FTD that has identified a number of promising therapeutic targets as well as animal models in which to develop drugs. The close association of some forms of FTD with neuropathological accumulation of tau protein or increased neuroinflammation due to progranulin protein… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 24 CITATIONS

Als and Ftd: Insights into the disease mechanisms and therapeutic targets.

  • European journal of pharmacology
  • 2017
VIEW 1 EXCERPT
CITES RESULTS

MicroRNA in neurodegenerative drug discovery: the way forward?

  • Expert opinion on drug discovery
  • 2015
VIEW 1 EXCERPT
CITES BACKGROUND

Similar Papers

Loading similar papers…